Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist

Experimental Eye Research

Volumn 88, Issue 1, 2009, Pages 106-112

  Wright, William S ^a   Messina, Jodine E ^a   Harris, Norman R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

blood flow; diabetes; mouse; retina; streptozotocin; thromboxane receptor antagonist; vapiprost

Indexed keywords

INSULIN; VAPIPROST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW VELOCITY; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG MECHANISM; HYPERGLYCEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD FLOW; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES; VASODILATATION;

ANIMALS; ARTERIOLES; BIPHENYL COMPOUNDS; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DRUG ADMINISTRATION SCHEDULE; HEPTANOIC ACIDS; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, THROMBOXANE; RETINAL ARTERY; RETINAL VEIN; RETINAL VESSELS; VASOCONSTRICTION; VENULES;

EID: 57549114645     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.10.008     Document Type: Article

References (44)

1. Ayalasomayajula S.P., and Kompella U.B. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur. J. Pharmacol. 458 (2003) 283-289
2. Bos C.L., Richel D.J., Ritsema T., Peppelenbosch M.P., and Versteeg H.H. Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell Biol. 36 (2004) 1187-1205
3. Braun R.D., Abbas A., Bukhari S.O., and Wilson III W. Hemodynamic parameters in blood vessels in choroidal melanoma xenografts and rat choroid. Invest. Ophthalmol. Vis. Sci. 43 (2002) 3045-3052
4. Bursell S.E., Clermont A.C., Kinsley B.T., Simonson D.C., Aiello L.M., and Wolpert H.A. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 37 (1996) 886-897
5. Bursell S.E., Clermont A.C., Shiba T., and King G.L. Evaluating retinal circulation using video fluorescein angiography in control and diabetic rats. Curr. Eye Res. 11 (1992) 287-295
6. Clermont A.C., Aiello L.P., Mori F., Aiello L.M., and Bursell S.E. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am. J. Ophthalmol. 124 (1997) 433-446
7. Clermont A.C., Brittis M., Shiba T., McGovern T., King G.L., and Bursell S.E. Normalization of retinal blood flow in diabetic rats with primary intervention using insulin pumps. Invest. Ophthalmol. Vis. Sci. 35 (1994) 981-990
8. Cosentino F., Eto M., De Paolis P., van der L.B., Bachschmid M., Ullrich V., Kouroedov A., Delli G.C., Joch H., Volpe M., and Luscher T.F. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 107 (2003) 1017-1023
9. de Gooyer T.E., Stevenson K.A., Humphries P., Simpson D.A., Gardiner T.A., and Stitt A.W. Retinopathy is reduced during experimental diabetes in a mouse model of outer retinal degeneration. Invest. Ophthalmol. Vis. Sci. 47 (2006) 5561-5568
10. De La Cruz J.P., Moreno A., Ruiz-Ruiz M.I., Garcia C.J., and Sanchez D.L.C. Effect of camonagrel, a selective thromboxane synthase inhibitor, on retinal vascularization in experimental diabetes. Eur. J. Pharmacol. 350 (1998) 81-85
11. De La Cruz J.P., Moreno A., Ruiz-Ruiz M.I., and Sanchez D.L.C. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus. Thromb. Res. 97 (2000) 125-131
12. De La Cruz P., Guerrero A., Paniego J., Arranz I., Moreno A., and Sanchez D.L.C. Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy. Naunyn Schmiedebergs Arch. Pharmacol. 365 (2002) 96-101
13. Esser P., Heimann K., and Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br. J. Ophthalmol. 77 (1993) 731-733
14. Fong D.S., Aiello L., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris III F.L., and Klein R. Diabetic retinopathy. Diabetes Care 26 (2003) 226-229
15. Granstam E., and Granstam S.O. Regulation of uveal and retinal blood flow in STZ-diabetic and non-diabetic rats; involvement of nitric oxide. Curr. Eye Res. 19 (1999) 330-337
16. Guth B.D., and Muller T.H. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res. Cardiol. 92 (1997) 181-190
17. Higashi S., Clermont A.C., Dhir V., and Bursell S.E. Reversibility of retinal flow abnormalities is disease-duration dependent in diabetic rats. Diabetes 47 (1998) 653-659
18. Horio N., Clermont A.C., Abiko A., Abiko T., Shoelson B.D., Bursell S.E., and Feener E.P. Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia 47 (2004) 113-123
19. Kanamori A., Nakamura M., Mukuno H., Maeda H., and Negi A. Diabetes has an additive effect on neural apoptosis in rat retina with chronically elevated intraocular pressure. Curr. Eye Res. 28 (2004) 47-54
20. Klein R., Klein B.E., Moss S.E., Wong T.Y., Hubbard L., Cruickshanks K.J., and Palta M. Retinal vascular abnormalities in persons with type 1 diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVIII. Ophthalmology 110 (2003) 2118-2125
21. Lasserre B., Navarro-Delmasure C., Pham Huu C.A., Catala J., and Hollande E. Modifications in the TXA(2) and PGI(2) plasma levels and some other biochemical parameters during the initiation and development of non-insulin-dependent diabetes mellitus (NIDDM) syndrome in the rabbit. Prostaglandins Leukot. Essent. Fatty Acids 62 (2000) 285-291
22. Lee S., and Harris N.R. Losartan and ozagrel reverse retinal arteriolar constriction in non-obese diabetic mice. Microcirculation 15 (2008) 379-387
23. Lee S., Morgan G.A., and Harris N.R. Ozagrel reverses streptozotocin-induced constriction of arterioles in rat retina. Microvasc. Res. 76 (2008) 217-223
24. Linsenmeier R.A., Braun R.D., McRipley M.A., Padnick L.B., Ahmed J., Hatchell D.L., McLeod D.S., and Lutty G.A. Retinal hypoxia in long-term diabetic cats. Invest. Ophthalmol. Vis. Sci. 39 (1998) 1647-1657
25. Mayhan W.G., Simmons L.K., and Sharpe G.M. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am. J. Physiol. 260 (1991) H319-H326
26. Moreno A., De La Cruz J.P., Garcia C.J., and Sanchez D.L.C. Prostacyclin-thromboxane balance and retinal vascular pattern in rats with experimentally induced diabetes. Can. J. Ophthalmol. 30 (1995) 117-123
27. Nagai N., Izumi-Nagai K., Oike Y., Koto T., Satofuka S., Ozawa Y., Yamashiro K., Inoue M., Tsubota K., Umezawa K., and Ishida S. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest. Ophthalmol. Vis. Sci. 48 (2007) 4342-4350
28. Pe'er J., Folberg R., Itin A., Gnessin H., Hemo I., and Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br. J. Ophthalmol. 80 (1996) 241-245
29. Pfister S.L., Hughes M.J., Rosolowsky M., and Campbell W.B. Role of contaminating platelets in thromboxane synthesis in primary cultures of human umbilical vein endothelial cells. Prostaglandins Other Lipid Mediat. 70 (2002) 39-49
30. Quilley J., and McGiff J.C. Arachidonic acid metabolism and urinary excretion of prostaglandins and thromboxane in rats with experimental diabetes mellitus. J. Pharmacol. Exp. Ther. 234 (1985) 211-216
31. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 48 (2005) 1439-1444
32. Roy M.S., Klein R., O'Colmain B.J., Klein B.E., Moss S.E., and Kempen J.H. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch. Ophthalmol. 122 (2004) 546-551
33. Shen R.F., and Tai H.H. Thromboxanes: synthase and receptors. J. Biomed. Sci. 5 (1998) 153-172
34. Small K.W., Stefansson E., and Hatchell D.L. Retinal blood flow in normal and diabetic dogs. Invest Ophthalmol. Vis. Sci. 28 (1987) 672-675
35. Sone H., Okuda Y., Kawakami Y., and Yamashita K. Effects of high glucose concentration and a thromboxane synthase inhibitor on the production of thromboxane A2 and prostaglandin I2 and E2 by retinal endothelial cells. Life Sci. 58 (1996) 239-243
36. Sun L.K., Wahl P., Bilic G., and Wuthrich R.P. CD44-mediated cyclooxygenase-2 expression and thromboxane A2 production in RAW 264.7 macrophages. Inflamm. Res. 50 (2001) 496-499
37. Tesfamariam B., Jakubowski J.A., and Cohen R.A. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2. Am. J. Physiol. 257 (1989) H1327-H1333
38. Thomas D.W., Mannon R.B., Mannon P.J., Latour A., Oliver J.A., Hoffman M., Smithies O., Koller B.H., and Coffman T.M. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J. Clin. Invest. 102 (1998) 1994-2001
39. Unthank J.L., Lash J.M., Nixon J.C., Sidner R.A., and Bohlen H.G. Evaluation of carbocyanine-labeled erythrocytes for microvascular measurements. Microvasc. Res. 45 (1993) 193-210
40. Wong T.Y., Klein R., Sharrett A.R., Schmidt M.I., Pankow J.S., Couper D.J., Klein B.E., Hubbard L.D., and Duncan B.B. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 287 (2002) 2528-2533
41. Wright W.S., and Harris N.R. Ozagrel attenuates early streptozotocin-induced constriction of arterioles in the mouse retina. Exp. Eye Res. 86 (2008) 528-536
42. Xu S., Jiang B., Maitland K.A., Bayat H., Gu J., Nadler J.L., Corda S., Lavielle G., Verbeuren T.J., Zuccollo A., and Cohen R.A. The thromboxane receptor antagonist s18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein e-deficient mice. Diabetes 55 (2006) 110-119
43. Yam J.C., and Kwok A.K. Update on the treatment of diabetic retinopathy. Hong Kong Med. J. 13 (2007) 46-60
44. Yamashiro K., Tsujikawa A., Ishida S., Usui T., Kaji Y., Honda Y., Ogura Y., and Adamis A.P. Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am. J. Pathol. 163 (2003) 253-259